[Prognostic value of pharmaco-EEG in depression treated with fluvoxamine].
14 patients (age 42.1 +/- 15.5; 12 women, 2 men) with a depressive episode (moderate, mild; ICD-10) were treated with fluvoxamine (150 mg). After 4 weeks two groups with different responses to the drug emerged (10 responders: improvement in Beck Inventory of Depression 13.6 +/- 2.9 and 4 nonresponders: 2.0 +/- 2.4). FFT analysis of their EEG (taken before and after the treatment) showed some relative power differences in most bands of frequencies between groups, mostly marked for à (7-14 Hz) and smaller for the others. Alpha activity was relatively low after treatment in nonresponders and slightly higher in responders. However, none of these results had statistical value.
Wiśniewski
Grzegorz
G
I Klinika Chorób Psychicznych Katedry Chorób Psychicznych AM w Gdańsku.
Jakitowicz
Janusz
J
Nowicki
Zbigniew
Z
D000328:Adult; D000368:Aged; D014151:Anti-Anxiety Agents / Q000008:administration & dosage*; D018687:Antidepressive Agents, Second-Generation / Q000008:administration & dosage*; D003866:Depressive Disorder / Q000188:drug therapy*; D004569:Electroencephalography / Q000187:drug effects*; D005260:Female; D016666:Fluvoxamine / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D011379:Prognosis; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage*; D013997:Time Factors; D016896:Treatment Outcome
D014151:Anti-Anxiety Agents; D018687:Antidepressive Agents, Second-Generation; D016666:Fluvoxamine; D017367:Selective Serotonin Reuptake Inhibitors